» Articles » PMID: 29516624

Synthesis and Pharmacological Evaluation of 2,3-diphenyl Acrylonitriles-bearing Halogen As Selective Anticancer Agents

Overview
Date 2018 Mar 9
PMID 29516624
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Eighteen novel 2,3-diphenyl acrylonitrile derivatives bearing halogens were designed, synthesized, and evaluated for biological activity. Preliminary in vitro results indicated that the majority of the compounds with a para-substituted halogen had considerable antiproliferative activity against five human cancer cell lines, including MGC-803, AGS, and BEL-7402, with IC values in the range of 0.46-100 μm. No significant toxic effects on the non-cancerous human liver cell line L-02 were observed. The selective inhibitory activities against cancer cells were significantly better than that of the control lead compound CA-4 and CA-4P. Particularly, potent activities were found for the derivatives of 3-(4-halogen phenyl)-2-(3,4,5-trimethoxyphenyl)acrylonitrile, such as 5c (4-fluoro), 5f (4-bromo), 5h (4-chloro), and 5k (4-trifluoro- methyl), for AGS with IC values of 0.75 ± 0.24, 0.68 ± 0.21, 0.41 ± 0.05, and 1.49 ± 0.92 μm, respectively. The antiproliferative effects of 5f were attributed to cell-cycle arrest in the G /M phase, induction of cellular apoptosis, suppression of cell migration, and inhibition of cell colony formation in AGS cells.

Citing Articles

Synthesis and Selective Anticancer Activity Evaluation of 2-phenylacrylonitrile Derivatives as Tubulin Inhibitors.

Jin Y, Xin Y, Li Y, Chen X, Man D, Tian Y Curr Med Chem. 2024; 31(15):2090-2106.

PMID: 38384112 PMC: 11071649. DOI: 10.2174/0109298673263854231009063053.


Design, Synthesis, and Anticancer Activity Evaluation of Hybrids of Azoles and Barbituric Acids.

Liu H, Huang X, Shen Q, Deng H, Li Z, Quan Z Iran J Pharm Res. 2021; 20(2):144-155.

PMID: 34567152 PMC: 8457749. DOI: 10.22037/ijpr.2020.113547.14363.


Acrylonitrile Derivatives against : In Vitro Activity and Programmed Cell Death Study.

Bethencourt-Estrella C, Delgado-Hernandez S, Lopez-Arencibia A, San Nicolas-Hernandez D, Sifaoui I, Tejedor D Pharmaceuticals (Basel). 2021; 14(6).

PMID: 34207767 PMC: 8228537. DOI: 10.3390/ph14060552.